Literature DB >> 14622621

Early antinociception delays edema but does not reduce the magnitude of persistent pain in the formalin test.

B K Taylor1, A I Basbaum.   

Abstract

Intraplantar formalin injection produces early (Phase 1, 0- to 5-minute) and late (Phase 2, 15-plus minutes after injection) nociceptive responses, including painlike behavior and activation of primary afferents and dorsal horn neurons. Although we and others have reported that opioid analgesia or local anesthesia during Phase 1 does not reduce the overall magnitude of behavioral and/or neuronal responses during Phase 2, recent studies concluded that spinal sensitization during Phase 1 significantly contributes to the magnitude of painlike behavior during Phase 2. In this article, we provide additional evidence that Phase 1 and Phase 2 behaviors are independent. We found that remifentanil analgesia during Phase 1 does not reduce Phase 2, regardless of route of administration, duration of analgesia, types of behavior assessed, formalin concentration, concomitant use of general anesthesia, or concomitant administration of an N-methyl-D-aspartate (NMDA) antagonist. We suggest that Phase 1 behaviors compared with Phase 2 behaviors in the formalin test are not an appropriate model of spinal sensitization or preemptive opioid analgesia. Instead, early opioid administration delayed the onset of edema produced by formalin. Because the antiedema effect of remifentanil was reversed with a peripherally acting opioid receptor antagonist, we suggest that opioids interact with peripheral receptors to temporarily delay the onset and offset of formalin-induced edema.

Entities:  

Year:  2000        PMID: 14622621     DOI: 10.1054/jpai.2000.7308

Source DB:  PubMed          Journal:  J Pain        ISSN: 1526-5900            Impact factor:   5.820


  5 in total

1.  Intrathecal neuropeptide Y reduces behavioral and molecular markers of inflammatory or neuropathic pain.

Authors:  A B Intondi; M N Dahlgren; M A Eilers; B K Taylor
Journal:  Pain       Date:  2007-10-31       Impact factor: 6.961

2.  TrkB signaling is required for both the induction and maintenance of tissue and nerve injury-induced persistent pain.

Authors:  Xidao Wang; Joseline Ratnam; Bende Zou; Pamela M England; Allan I Basbaum
Journal:  J Neurosci       Date:  2009-04-29       Impact factor: 6.167

3.  Synergistic analgesia of duloxetine and celecoxib in the mouse formalin test: a combination analysis.

Authors:  Yong-Hai Sun; Yu-Lin Dong; Yu-Tong Wang; Guo-Li Zhao; Gui-Jun Lu; Jing Yang; Sheng-Xi Wu; Ze-Xu Gu; Wen Wang
Journal:  PLoS One       Date:  2013-10-07       Impact factor: 3.240

4.  The formalin test does not probe inflammatory pain but excitotoxicity in rodent skin.

Authors:  Tal Hoffmann; Florian Klemm; Tatjana I Kichko; Susanne K Sauer; Katrin Kistner; Bernhard Riedl; Patrick Raboisson; Lei Luo; Alexandru Babes; Laurence Kocher; Giancarlo Carli; Michael J M Fischer; Peter W Reeh
Journal:  Physiol Rep       Date:  2022-03

5.  Low-molecular synthetic peptides with non-narcotic type of analgesia: comparative study and mechanism of analgesic activity.

Authors:  Arkady M Kotin; Maksim O Emelyanov; Oleg A Kotin
Journal:  Mol Pain       Date:  2019 Jan-Dec       Impact factor: 3.395

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.